MA54955A - Anticorps anti-claudine 6 et leurs utilisations - Google Patents

Anticorps anti-claudine 6 et leurs utilisations

Info

Publication number
MA54955A
MA54955A MA054955A MA54955A MA54955A MA 54955 A MA54955 A MA 54955A MA 054955 A MA054955 A MA 054955A MA 54955 A MA54955 A MA 54955A MA 54955 A MA54955 A MA 54955A
Authority
MA
Morocco
Prior art keywords
claudine
antibodies
Prior art date
Application number
MA054955A
Other languages
English (en)
Inventor
Trevor Barnes
Ross Chambers
Thomas Charpentier
Benjamin Doranz
Joseph Rucker
Brad Screnci
Lewis J Stafford
Original Assignee
Integral Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Molecular Inc filed Critical Integral Molecular Inc
Publication of MA54955A publication Critical patent/MA54955A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA054955A 2019-02-15 2020-02-13 Anticorps anti-claudine 6 et leurs utilisations MA54955A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806048P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
MA54955A true MA54955A (fr) 2021-12-22

Family

ID=72043303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054955A MA54955A (fr) 2019-02-15 2020-02-13 Anticorps anti-claudine 6 et leurs utilisations

Country Status (18)

Country Link
US (2) US11248046B2 (fr)
EP (1) EP3924389A4 (fr)
KR (1) KR20210128443A (fr)
CN (1) CN113767113A (fr)
AU (1) AU2020223293A1 (fr)
BR (1) BR112021016056A2 (fr)
CA (1) CA3129834A1 (fr)
CL (1) CL2021002141A1 (fr)
CO (1) CO2021011906A2 (fr)
CR (1) CR20210471A (fr)
EA (1) EA202192146A1 (fr)
EC (1) ECSP21068097A (fr)
IL (1) IL285626A (fr)
MA (1) MA54955A (fr)
MX (1) MX2021009831A (fr)
SG (1) SG11202108281UA (fr)
WO (1) WO2020168059A1 (fr)
ZA (1) ZA202106602B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3129317A1 (fr) * 2019-02-15 2020-08-20 Integral Molecular, Inc. Anticorps comprenant une chaine legere commune et leurs utilisations
CN113767113A (zh) 2019-02-15 2021-12-07 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
TW202246323A (zh) * 2021-03-02 2022-12-01 美商諾瓦拉克生物醫療有限公司 抗ｃｌａｕｄｉｎ—６之抗體及其用途
WO2023053282A1 (fr) * 2021-09-29 2023-04-06 中外製薬株式会社 Agent thérapeutique induisant la cytotoxicité destiné à être utilisé dans le traitement du cancer
WO2023230624A2 (fr) * 2022-05-27 2023-11-30 Taipei Medical University Anticorps ciblant epha2 et leurs applications dans le traitement du cancer
WO2024118771A1 (fr) * 2022-11-30 2024-06-06 Integral Molecular, Inc. Anticorps dirigés contre la claudine 6, notamment des formats bispécifiques de ceux-ci

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (fr) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP2192131A1 (fr) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulines dépourvus de chaînes légères
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6004746A (en) 1994-07-20 1999-12-21 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE60044514D1 (de) 1999-05-05 2010-07-15 Phylogica Ltd Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielvältigen Genfragmenten
DE60045243D1 (de) 1999-05-26 2010-12-30 Next Biomed Technologies Nbt Oy VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
WO2002020565A2 (fr) 2000-09-08 2002-03-14 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
EP2284270A3 (fr) 2000-12-13 2012-07-25 Anaphore, Inc. Procédé d'identification et d'isolation des polypeptides de liaison à partir des bibliothèques combinatoires de protéines dotées d'une structure d'échafaudage des domaines par exemple de la lectine de type C
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
KR20100109969A (ko) 2002-10-02 2010-10-11 카탈리스트 바이오사이언시즈, 인코포레이티드 변경된 특이성을 갖는 프로테아제의 제조 및 선별 방법
DE602004031589D1 (de) 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8377691B2 (en) 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
EP1892248A1 (fr) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Protéines liantes spécifiques et de haute affinité comprenant des domaines SH3 de FYN kinase modifiés
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
WO2009025759A1 (fr) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Protéines de jonction serrée associées à une infection et entrée du virus de l'hépatite c (vhc), procédés et utilisations de celles-ci
KR20100116179A (ko) 2008-01-11 2010-10-29 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항-ｃｌｄｎ6 항체
CA2749539C (fr) 2009-01-21 2022-07-19 Amgen Inc. Compositions et methodes comprenant des mutants d'interleukine-2 destinees au traitement de maladies inflammatoires et auto-immunes
US9074002B2 (en) * 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
EP2322555A1 (fr) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Anticorps spécifiques pour claudin 6 (CLDN6)
NZ734307A (en) 2009-11-11 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011096528A1 (fr) 2010-02-04 2011-08-11 東レ株式会社 Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP2404936A1 (fr) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
EP2655409A4 (fr) 2010-12-22 2015-07-01 Univ Leland Stanford Junior Super-agonistes et antagonistes de l'interleukine-2
KR102072183B1 (ko) * 2011-05-13 2020-02-03 가니메드 파마슈티칼스 게엠베하 클라우딘 6을 발현하는 암 치료용 항체
WO2013056115A1 (fr) 2011-10-14 2013-04-18 Ergotron, Inc. Systèmes et procédés de bras de montage de tablette
JP2015505326A (ja) 2012-01-18 2015-02-19 ニューメディシンズ，インコーポレーテッド 放射線防護及び放射線誘発性毒性緩和のためのｉｌ−１２
WO2014016737A1 (fr) 2012-07-24 2014-01-30 Pfizer Inc. Nouveaux anticorps monoclonaux de poulet dirigés contre la protéine tau phosphorylée humaine et leurs utilisations
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
CN103483449A (zh) * 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
IL289475B2 (en) 2014-07-21 2023-10-01 Delinia Inc Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases
EP3482766B1 (fr) 2014-08-11 2020-05-20 Delinia, Inc. Variantes il-2 modifiées d'activation sélective de lymphocytes t régulateurs pour le traitement de maladies auto-immunes
CA2874083C (fr) * 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
WO2016143753A1 (fr) 2015-03-06 2016-09-15 公立大学法人横浜市立大学 Nouveaux anticorps anti-pad4
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
AU2016364853A1 (en) 2015-12-04 2018-06-21 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
CA3022961A1 (fr) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anticorps anti-kv 1.3 et procedes pour les produire et les utiliser
CN115073581A (zh) 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
WO2018054484A1 (fr) 2016-09-23 2018-03-29 Biontech Ag Anticorps trivalents bispécifiques se liant à claudine 6 ou claudin18.2 et cd3 pour le traitement de maladies cancéreuses exprimant la claudine
WO2018067198A1 (fr) 2016-10-03 2018-04-12 The Regents Of The University Of California Anticorps inhibiteurs et leurs procédés d'utilisation
WO2019048040A1 (fr) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Anticorps utiles dans le diagnostic du cancer
SG11202002114RA (en) 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
WO2020075325A1 (fr) 2018-10-09 2020-04-16 公立大学法人福島県立医科大学 Biomarqueur pour prédire le pronostic d'un patient atteint d'un cancer de l'endomètre
CN113767113A (zh) 2019-02-15 2021-12-07 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
CA3129317A1 (fr) 2019-02-15 2020-08-20 Integral Molecular, Inc. Anticorps comprenant une chaine legere commune et leurs utilisations
BR112021018608A2 (pt) 2019-03-20 2021-11-23 Univ California Anticorpos para claudina-6 e conjugados de fármaco
CN113950485A (zh) 2019-07-10 2022-01-18 中外制药株式会社 密蛋白-6结合分子及其用途

Also Published As

Publication number Publication date
EP3924389A1 (fr) 2021-12-22
BR112021016056A2 (pt) 2021-12-14
ZA202106602B (en) 2023-12-20
IL285626A (en) 2021-09-30
JP2022521723A (ja) 2022-04-12
CA3129834A1 (fr) 2020-08-20
ECSP21068097A (es) 2021-11-18
US11248046B2 (en) 2022-02-15
AU2020223293A1 (en) 2021-08-19
CR20210471A (es) 2021-12-08
WO2020168059A1 (fr) 2020-08-20
US20220127355A1 (en) 2022-04-28
CN113767113A (zh) 2021-12-07
SG11202108281UA (en) 2021-08-30
CL2021002141A1 (es) 2022-04-01
US20200262915A1 (en) 2020-08-20
MX2021009831A (es) 2021-09-10
KR20210128443A (ko) 2021-10-26
EA202192146A1 (ru) 2021-11-09
CO2021011906A2 (es) 2021-09-30
EP3924389A4 (fr) 2023-06-14

Similar Documents

Publication Publication Date Title
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
MA52426A (fr) Conjugués d'il-15 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA53168A (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA52414A (fr) Anticorps agonistes de pd-1 et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA54955A (fr) Anticorps anti-claudine 6 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA52022A (fr) Anticorps qui se lient à cd39 et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
MA52094A (fr) Anticorps anti-il-27 et leurs utilisations
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations